Cargando…

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

The objectives of this study were to characterize the pharmacokinetics (PK) of LY2510924, a potent peptide antagonist of the CXCR4 receptor, after subcutaneous administration in patients with advanced cancer forms and quantify LY2510924 stimulatory effects on the mobilization of cells bearing the cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bihorel, S, Raddad, E, Fiedler‐Kelly, J, Stille, JR, Hing, J, Ludwig, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613202/ https://www.ncbi.nlm.nih.gov/pubmed/28643374 http://dx.doi.org/10.1002/psp4.12221

Ejemplares similares

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017)

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
por: O'Hara, Mark H., et al.
Publicado: (2020)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

C-terminal–modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4
por: Suzuki, Kentaro, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Cho B-S, Zeng Z, Mu H, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126(2):222-232.
Publicado: (2015)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis
por: Naik, Himanshu, et al.
Publicado: (2013)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma
por: Chatterjee, MS, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics
por: Wacheck, Volker, et al.
Publicado: (2011)

A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519
por: Kim, Choon Ok, et al.
Publicado: (2020)

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design
por: Reddy, Micaela B., et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
por: Alghamdi, Wael A., et al.
Publicado: (2019)

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
por: Li, Jianguo, et al.
Publicado: (2018)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
por: Papasouliotis, Orestis, et al.
Publicado: (2022)

Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
por: Bender, Brendan C, et al.
Publicado: (2015)

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
por: Bi, Youwei, et al.
Publicado: (2018)

Fractional dynamics pharmacokinetics–pharmacodynamic models
por: Verotta, Davide
Publicado: (2010)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment‐Refractory Depression
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Introduction to Population Pharmacokinetic/Pharmacodynamic Analysis With Nonlinear Mixed Effects Models
por: Graaf, P H van der
Publicado: (2014)

Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass
por: Hornik, Christoph P., et al.
Publicado: (2019)

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Kloprogge, Frank, et al.
Publicado: (2020)

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
por: Sridharan, Kannan, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents
por: Luo, Wanhe, et al.
Publicado: (2019)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)

Alfaxalone population pharmacokinetics in the rat: Model application for pharmacokinetic and pharmacodynamic design in inbred and outbred strains and sexes
por: White, Kate, et al.
Publicado: (2022)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
por: Diekstra, MH, et al.
Publicado: (2017)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6slmk37i5uk9cp5mnk1gfm2j3n